141 related articles for article (PubMed ID: 36963751)
1. RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
Fujii S; Kobayashi S; Chang Y; Nawata J; Yoshitomi R; Tanaka S; Kohno M; Nakamura Y; Ishiguchi H; Suetomi T; Uchinoumi H; Oda T; Okuda S; Okamura T; Yamamoto T; Yano M
J Mol Cell Cardiol; 2023 May; 178():36-50. PubMed ID: 36963751
[TBL] [Abstract][Full Text] [Related]
2. Stabilizing cardiac ryanodine receptor with dantrolene treatment prevents left ventricular remodeling in pressure-overloaded heart failure mice.
Yano Y; Kobayashi S; Uchida T; Chang Y; Nawata J; Fujii S; Nakamura Y; Suetomi T; Uchinoumi H; Oda T; Yamamoto T; Yano M
Biochem Biophys Res Commun; 2023 Jan; 642():175-184. PubMed ID: 36584481
[TBL] [Abstract][Full Text] [Related]
3. RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease.
Schmeckpeper J; Kim K; George SA; Blackwell DJ; Brennan JA; Efimov IR; Knollmann BC
J Mol Cell Cardiol; 2023 Aug; 181():67-78. PubMed ID: 37285929
[TBL] [Abstract][Full Text] [Related]
4. Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function, and prevents sudden arrhythmic death in failing hearts.
Joshi P; Estes S; DeMazumder D; Knollmann BC; Dey S
Elife; 2023 Dec; 12():. PubMed ID: 38078905
[TBL] [Abstract][Full Text] [Related]
5. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift.
Uchinoumi H; Yang Y; Oda T; Li N; Alsina KM; Puglisi JL; Chen-Izu Y; Cornea RL; Wehrens XHT; Bers DM
J Mol Cell Cardiol; 2016 Sep; 98():62-72. PubMed ID: 27318036
[TBL] [Abstract][Full Text] [Related]
6. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing cardiac ryanodine receptor prevents the development of cardiac dysfunction and lethal arrhythmia in Ca
Sufu-Shimizu Y; Okuda S; Kato T; Nishimura S; Uchinoumi H; Oda T; Kobayashi S; Yamamoto T; Yano M
Biochem Biophys Res Commun; 2020 Apr; 524(2):431-438. PubMed ID: 32007269
[TBL] [Abstract][Full Text] [Related]
8. Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction.
Xu X; Yano M; Uchinoumi H; Hino A; Suetomi T; Ono M; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ikemoto N; Matsuzaki M
Biochem Biophys Res Commun; 2010 Apr; 394(3):660-6. PubMed ID: 20226167
[TBL] [Abstract][Full Text] [Related]
9. Dantrolene prevents ventricular tachycardia by stabilizing the ryanodine receptor in pressure- overload induced failing hearts.
Kajii T; Kobayashi S; Shiba S; Fujii S; Tamitani M; Kohno M; Nakamura Y; Nanno T; Kato T; Okuda S; Uchinoumi H; Oda T; Yamamoto T; Yano M
Biochem Biophys Res Commun; 2020 Jan; 521(1):57-63. PubMed ID: 31635807
[TBL] [Abstract][Full Text] [Related]
10. Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure.
Yang Y; Guo T; Oda T; Chakraborty A; Chen L; Uchinoumi H; Knowlton AA; Fruen BR; Cornea RL; Meissner G; Bers DM
Circ Res; 2014 Jan; 114(2):295-306. PubMed ID: 24186966
[TBL] [Abstract][Full Text] [Related]
11. Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors.
Seidel M; Thomas NL; Williams AJ; Lai FA; Zissimopoulos S
Cardiovasc Res; 2015 Jan; 105(1):118-28. PubMed ID: 25411383
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction.
Zhang H; Makarewich CA; Kubo H; Wang W; Duran JM; Li Y; Berretta RM; Koch WJ; Chen X; Gao E; Valdivia HH; Houser SR
Circ Res; 2012 Mar; 110(6):831-40. PubMed ID: 22302785
[TBL] [Abstract][Full Text] [Related]
13. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.
Suetomi T; Yano M; Uchinoumi H; Fukuda M; Hino A; Ono M; Xu X; Tateishi H; Okuda S; Doi M; Kobayashi S; Ikeda Y; Yamamoto T; Ikemoto N; Matsuzaki M
Circulation; 2011 Aug; 124(6):682-94. PubMed ID: 21768539
[TBL] [Abstract][Full Text] [Related]
14. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes.
Fukuda M; Yamamoto T; Nishimura S; Kato T; Murakami W; Hino A; Ono M; Tateishi H; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
Biochem Biophys Res Commun; 2014 May; 448(1):1-7. PubMed ID: 24755079
[TBL] [Abstract][Full Text] [Related]
15. Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia.
Nakamura Y; Yamamoto T; Kobayashi S; Tamitani M; Hamada Y; Fukui G; Xu X; Nishimura S; Kato T; Uchinoumi H; Oda T; Okuda S; Yano M
JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167968
[TBL] [Abstract][Full Text] [Related]
16. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
[TBL] [Abstract][Full Text] [Related]
17. Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity.
Oda T; Yang Y; Uchinoumi H; Thomas DD; Chen-Izu Y; Kato T; Yamamoto T; Yano M; Cornea RL; Bers DM
J Mol Cell Cardiol; 2015 Aug; 85():240-8. PubMed ID: 26092277
[TBL] [Abstract][Full Text] [Related]
18. Correction of impaired calmodulin binding to RyR2 as a novel therapy for lethal arrhythmia in the pressure-overloaded heart failure.
Kato T; Yamamoto T; Nakamura Y; Nanno T; Fukui G; Sufu Y; Hamada Y; Maeda T; Nishimura S; Ishiguchi H; Murakami W; Fukuda M; Xu X; Hino A; Ono M; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
Heart Rhythm; 2017 Jan; 14(1):120-127. PubMed ID: 27771553
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of calmodulin from cardiac ryanodine receptor causes aberrant Ca(2+) release in heart failure.
Ono M; Yano M; Hino A; Suetomi T; Xu X; Susa T; Uchinoumi H; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Koseki N; Kyushiki H; Ikemoto N; Matsuzaki M
Cardiovasc Res; 2010 Sep; 87(4):609-17. PubMed ID: 20388639
[TBL] [Abstract][Full Text] [Related]
20. Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload.
Sedej S; Schmidt A; Denegri M; Walther S; Matovina M; Arnstein G; Gutschi EM; Windhager I; Ljubojević S; Negri S; Heinzel FR; Bisping E; Vos MA; Napolitano C; Priori SG; Kockskämper J; Pieske B
J Am Coll Cardiol; 2014 Apr; 63(15):1569-79. PubMed ID: 24315909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
